Skip to content

Study · Randomized controlled trial · n = 60 · 2016

6 results

Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke.

Xue LX, Zhang T, Zhao YW, Geng Z, Chen JJ, Chen H

Experimental and therapeutic medicine10 Mar 2016Cited by 56 (Europe PMC)

PMID27168844 (opens in a new tab)PMCIDPMC4840538 (opens in a new tab)DOI10.3892/etm.2016.3139 (opens in a new tab)PepBankPUB-27168844
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In acute ischemic stroke patients, adverse event rates did not differ significantly among Cerebrolysin, NBP, and placebo groups.

    In plain wordsIn stroke patients, adverse event rates did not differ significantly among Cerebrolysin, NBP, and placebo groups.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeAdverse event rate across all groups
    Study

    n = 60

    Comparator
    NBP and placebo groups
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intravenous · 10-dayAs given in this study (human).

    Source sentences

    Summary
    No significant difference was found among the three groups with regard to the rate of adverse events.
    2 context sentences
    Summary · context
    A randomized, double-blind trial was conducted with enrolment of 60 patients within 12 h of AIS.
    Summary · context
    In addition to routine treatment, patients were randomly assigned to receive a 10-day intravenous administration of NBP, Cerebrolysin or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke patients, Cerebrolysin produced greater NIHSS improvement than placebo at day 11.

    In plain wordsIn stroke patients, Cerebrolysin improved neurological scores more than placebo at day 11.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNIHSS improvement at day 11
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intravenous · 10-dayAs given in this study (human).

    Measurements

    P value for NIHSS improvement
    < 0.05
    Cerebrolysin versus placebo at day 11

    Source sentences

    Summary
    The improvements of NIHSS and BI scores in the NBP and Cerebrolysin groups were higher than those in the placebo group at days 11 and 21 (P<0.05).
    2 context sentences
    Summary · context
    A randomized, double-blind trial was conducted with enrolment of 60 patients within 12 h of AIS.
    Summary · context
    In addition to routine treatment, patients were randomly assigned to receive a 10-day intravenous administration of NBP, Cerebrolysin or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke patients, Cerebrolysin produced greater NIHSS improvement than placebo at day 21.

    In plain wordsIn stroke patients, Cerebrolysin improved neurological scores more than placebo at day 21.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNIHSS improvement at day 21
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intravenous · 10-dayAs given in this study (human).

    Measurements

    P value for NIHSS improvement
    < 0.05
    Cerebrolysin versus placebo at day 21

    Source sentences

    Summary
    The improvements of NIHSS and BI scores in the NBP and Cerebrolysin groups were higher than those in the placebo group at days 11 and 21 (P<0.05).
    3 context sentences
    Summary · context
    After 10 days of treatment with NBP or Cerebrolysin, the NIHSS and BI scores at day 21 showed statistical differences compared with those in the placebo group (P<0.05).
    Summary · context
    A randomized, double-blind trial was conducted with enrolment of 60 patients within 12 h of AIS.
    Summary · context
    In addition to routine treatment, patients were randomly assigned to receive a 10-day intravenous administration of NBP, Cerebrolysin or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke patients, Cerebrolysin produced greater Barthel Index improvement than placebo at day 11.

    In plain wordsIn stroke patients, Cerebrolysin improved daily-function scores more than placebo at day 11.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBarthel Index improvement at day 11
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · intravenous · 10-dayAs given in this study (human).

    Measurements

    P value for Barthel Index improvement
    < 0.05
    Cerebrolysin versus placebo at day 11

    Source sentences

    Summary
    The improvements of NIHSS and BI scores in the NBP and Cerebrolysin groups were higher than those in the placebo group at days 11 and 21 (P<0.05).
    2 context sentences
    Summary · context
    A randomized, double-blind trial was conducted with enrolment of 60 patients within 12 h of AIS.
    Summary · context
    In addition to routine treatment, patients were randomly assigned to receive a 10-day intravenous administration of NBP, Cerebrolysin or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke patients, Cerebrolysin produced greater Barthel Index improvement than placebo at day 21.

    In plain wordsIn stroke patients, Cerebrolysin improved daily-function scores more than placebo at day 21.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBarthel Index improvement at day 21
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · intravenous · 10-dayAs given in this study (human).

    Measurements

    P value for Barthel Index improvement
    < 0.05
    Cerebrolysin versus placebo at day 21

    Source sentences

    Summary
    The improvements of NIHSS and BI scores in the NBP and Cerebrolysin groups were higher than those in the placebo group at days 11 and 21 (P<0.05).
    3 context sentences
    Summary · context
    After 10 days of treatment with NBP or Cerebrolysin, the NIHSS and BI scores at day 21 showed statistical differences compared with those in the placebo group (P<0.05).
    Summary · context
    A randomized, double-blind trial was conducted with enrolment of 60 patients within 12 h of AIS.
    Summary · context
    In addition to routine treatment, patients were randomly assigned to receive a 10-day intravenous administration of NBP, Cerebrolysin or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke patients, improvement of day 21 NIHSS scores differed significantly between Cerebrolysin and NBP, with direction unstated.

    In plain wordsIn stroke patients, neurological score improvement differed between Cerebrolysin and NBP at day 21. The result sentence does not state direction.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedNIHSS improvement versus NBP at day 21
    Study

    n: not reported in source

    Comparator
    DL-3-n-butylphthalide
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intravenous · 10-dayAs given in this study (human).

    Measurements

    P value for NIHSS improvement
    < 0.05
    Cerebrolysin versus NBP at day 21

    Source sentences

    Summary
    A statistically significant difference in the improvement of 21-day NIHSS scores was observed between the two treatment groups (P<0.05).
    2 context sentences
    Summary · context
    A randomized, double-blind trial was conducted with enrolment of 60 patients within 12 h of AIS.
    Summary · context
    In addition to routine treatment, patients were randomly assigned to receive a 10-day intravenous administration of NBP, Cerebrolysin or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1/2Results postedNCT02149875

Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke

Shanghai 6th People's Hospitaln = 84Jan 2010 to May 2010

Acute Cerebral Stroke Within 12 Hours for the First Time

Trial pageClinicalTrials.govUpdated 24 Aug 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.